Tirzepatide (Mounjaro) - 90 Day (Subscription)

Available Nationwide (ALL 50 States!) Tirzepatide is a novel, FDA approved, medication for the treatment of type 2 diabetes mellitus and obesity treatment. It works as a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Activation of these receptors results in slower stomach emptying and stimulation of insulin release from the pancreas. Many patients also note a significant decrease in appetite which can lead to weight loss.The primary adverse effects reported are GI-related and include nausea, diarrhea/constipation and GERD. If Tirzepatide is continued long-term pancreatitis and gallstone formation may be possible side effects as well.  Animal studies have shown a potential of developing medullary thyroid carcinoma with usage of Tirzepatide. It is uncertain what the risks of this occurring in humans is at the present time. Given the theoretical risk, tirzepatide should be avoided in those with a personal or family history of thyroid cancer